AstraZeneca and RQ Biotechnology Sign License Agreement for Monoclonal Antibodies

Published on: 

AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.

AstraZeneca has entered into a license agreement with RQ Biotechnology, a company focused on developing treatments and preventative therapies based on mAbs, for early-stage monoclonal antibodies (mAbs) targeted against COVID-19. Under the agreement, AstraZeneca will have an exclusive worldwide license to develop, manufacture, and commercialize mAbs.

RQ Biotechnology specifically focuses on addressing areas of unmet need in vulnerable patient populations through the use of potent broad-spectrum mAbs.

“The COVID-19 pandemic has changed the landscape for immune therapies, including the use of monoclonal antibodies to protect vulnerable patients who can’t respond adequately to vaccination alone,” said Iskra Reic, executive vice president, vaccine & immune therapies, AstraZeneca. “Scientific innovation is rapidly accelerating, and this agreement reflects our continued commitment to the discovery and development of new medicines to help prevent and treat infectious disease, including COVID-19.”


Source: AstraZeneca